Spero Therapeutics, Inc. (SPRO) News
Track canonical SquawkNews coverage tagged to SPRO, Spero Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 5 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
SPRO Announces Q2 2026 Operating Results
Spero Therapeutics announces second quarter 2026 operating results and provides business update
EARNINGS | Aug 12, 2026, 08:01 PM UTC
L
SPRO - Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
SPRO - Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
EARNINGS | Aug 04, 2026, 08:01 PM UTC
H
Sector Update: Healthcare Stocks Mixed Premarket Tuesday
() -- Healthcare stocks were mixed premarket Tuesday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.3% and the iShares Biotechnology ETF (IBB) 0.1% higher. HCA Healthcare (HCA) shares were down mo
EARNINGS | Jul 14, 2026, 01:16 PM UTC
L
SPRO IVBIY innovent Biologics and Spero Therapeutics announce exclusive license for ibi355 (sp001), a phase 2-ready third-generation anti-cd
SPRO IVBIY innovent Biologics and Spero Therapeutics announce exclusive license for ibi355 (sp001), a phase 2-ready third-generation anti-cd40l antibody Innovent Biologics - Spero receives exclusive global rights to ibi3
GEOPOLITICS | Jul 14, 2026, 10:26 AM UTC
H
Spero Therapeutics Announces $105M In Non-Recourse Non-Dilutive Royalty Financing With KKR's Healthcare Royalty
Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil) milestones and roya
EARNINGS | Jul 14, 2026, 10:11 AM UTC